Lobbying Filing Details

Total Spending

$450,000

Activities

2

Lobbyists

1

Gov't Entities

4

Filing Information
Filing UUID:
f272a99e-5598-4113-8a7b-3529a8bd9baf
Type:
Q2 - 2nd Quarter - Report
Period:
2024 - 2nd Quarter (Apr 1 - June 30)
Date Posted:
July 22, 2024 at 6:12 PM
Income:
$0
Expenses:
$450,000
Expense Method:
A
Document URL:
View Submission
Quick Info
  • Document Type: text/html
  • Posted By: Michael Mattoon, Vice President, Government Affairs & Policy - Acadia Pharmaceuticals
Registrant
ACADIA PHARMACEUTICALS

Biopharmaceutical company

San Diego, California
Client
ACADIA PHARMACEUTICALS
California, United States of America
Lobbying Activities (2)
Activity 1
Health Issues

Implementation of the Inflation Reduction Act of 2022; Help Copays Act (HR 830 / S 1375); Orphan Cures Act (HR 5539 / S 3131); National Plan to End Parkinson's Act (HR 2365 / S 1064); Protect Rare Act (HR 6094); The Creating Hope Reauthorization Act (HR 7384 / S 4583); Protecting and Preserving Social Security Act (S 4583).

Lobbyists (1)
  • MR. MICHAEL MATTOON
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES
Activity 2
Medicare/Medicaid

Implementation of the Inflation Reduction Act of 2022; Issues related to protecting patient access to medicines in Medicare; Issues related to access to medicines for Parkinson's disease patients; Issues Related to Antipsychotic use in Medicaid (HR 4096); Orphan Cures Act (HR 5539 / S 3131); National Plan to End Parkinson's Act (HR 2365 / S 1064); Protect Rare Act (HR 6094); EPIC Act (HR 7174).

Lobbyists (1)
  • MR. MICHAEL MATTOON
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES

Source: LDA.gov, data retrieved November 11, 2026. FilingExplorer is not affiliated with LDA.gov; the Senate Office of Public Records cannot vouch for data or analyses derived from these records after retrieval.